Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-19 · accession 0001336504-25-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-23 | 2025-12-19 | OLMA | CLARK IAN T | Dir | M - OptEx | $4.61 | +264.8K | 264.8K | New | +$1.22M |
| DM | 2025-12-23 | 2025-12-19 | OLMA | CLARK IAN T | Dir | S - Sale+OE | $29.73 | -264.8K | 0 | -100% | -$7.87M |
| DM | 2025-12-23 | 2025-12-19 | OLMA | CLARK IAN T | Dir | M - OptEx | $0.00 | -264.8K | 12.1K | -96% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-19 | M | A | 209,690 | $4.41 | 209,690 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-19 | M | A | 21,520 | $3.61 | 231,210 | D | — | — | |
| 3 | Common | Common Stock | 2025-12-19 | M | A | 21,520 | $7.84 | 252,730 | D | — | — | |
| 4 | Common | Common Stock | 2025-12-19 | M | A | 12,070 | $4.08 | 264,800 | D | — | — | |
| 5 | Common | Common Stock | 2025-12-19 | S | D | 29,904 | $28.83 | 234,896 | D | — | — | (F1) The weighted average sale price for the transaction reported was $28.83, and the range of prices was between $28.215 and $29.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 6 | Common | Common Stock | 2025-12-19 | S | D | 193,056 | $29.71 | 41,840 | D | — | — | (F2) The weighted average sale price for the transaction reported was $29.71, and the range of prices was between $29.22 and $30.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 7 | Common | Common Stock | 2025-12-19 | S | D | 41,840 | $30.48 | 0 | D | — | — | (F3) The weighted average sale price for the transaction reported was $30.48, and the range of prices was between $30.23 and $30.995. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 8 | Derivative | Stock Option (Right to Buy) | 2025-12-19 | M | D | 209,690 | $0.00 | 0 | D | $4.41 · — to 2023-08-11 | 209,690 Common Stock | (F4) Fully vested. |
| 9 | Derivative | Stock Option (Right to Buy) | 2025-12-19 | M | D | 21,520 | $0.00 | 0 | D | $3.61 · — to 2032-06-16 | 21,520 Common Stock | (F4) Fully vested. |
| 10 | Derivative | Stock Option (Right to Buy) | 2025-12-19 | M | D | 21,520 | $0.00 | 0 | D | $7.84 · — to 2033-06-15 | 21,520 Common Stock | (F4) Fully vested. |
| 11 | Derivative | Stock Option (Right to Buy) | 2025-12-19 | M | D | 12,070 | $0.00 | 12,080 | D | $4.08 · — to 2035-06-11 | 12,070 Common Stock | (F5) The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. |